Compass Pathways PLC 10-Q quarterly reports

Compass Pathways plc announced its Q2 2026 financial results, detailing continued progress in its clinical trials for COMP360 psilocybin treatment but also reporting significant operating losses and a substantial accumulated deficit.

Compass Pathways plc announced its first quarter 2026 financial results, highlighting significant progress in its Phase 3 clinical trials for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), alongside a substantial increase in cash reserves.

COMPASS Pathways reported a significant increase in net loss for Q3 2025, driven by warrant liability revaluation, while advancing its COMP360 psilocybin treatment in Phase 3 trials for TRD and a late-stage program for PTSD.

COMPASS Pathways announced positive top-line primary endpoint data from its first Phase 3 trial for treatment-resistant depression (TRD) and extended its cash runway into 2027, despite ongoing operating losses.

Compass Pathways amends its research collaboration agreement with Kings College London and South London and Maudsley NHS Foundation Trust, and files its Q1 2025 report, highlighting financial strategies and clinical trial advancements.

COMPASS Pathways announces its third quarter 2024 financial results alongside a strategic reorganization to focus on its Phase 3 program for treatment-resistant depression.

COMPASS Pathways reports a net loss of $73.3 million for the first half of 2024, while highlighting progress in its Phase 3 clinical program for COMP360 psilocybin treatment.

COMPASS Pathways reports a net loss of $35.2 million for Q1 2024, but maintains a strong cash position extending its runway into 2026.